cd-40

Corticosterone (Kendall's compound B) is an adrenocortical steroid with salocorticoid and glucocorticoid activity that is orally active. Corticosterone is involved in the regulation of energy, immune responses, and stress responses in the body.

Teneliximab (BMS 224819) is a chimeric monoclonal antibody and a tumor necrosis factor receptor superfamily member 5 (CD40) inhibitor that blocks CD40-CD40L interactions.Teneliximab exerts its partial agonist activity through CD40 and peripheral B-cell depletion, and may be used to study organ transplant rejection and rheumatoid arthritis.

Mitazalimab (ADC-1013) is a monoclonal IgG antibody targeting CD40 and a CD40 agonist with antitumor activity. Mitazalimab activates antigen-presenting cells, induces transient peripheral transcriptome changes, and can be used to study tumors.

Omalizumab is a recombinant humanized monoclonal antibody against human immunoglobulin E IgE)

TRAF-STOP inhibitor 6877002 (CD40-TRAF6 inhibitor), is a selective inhibitor of CD40-TRAF6 interaction. TRAF-STOP 6877002 reduces leukocyte recruitment, and reduces macrophage activation; reduces macrophage proliferation in atherosclerotic plaques.

UNC9426 is an orally active, potent and selective TYRO3 inhibitor with an IC50 of 2.1 nM. It reduces platelet aggregation without prolonging bleeding time and blocks TYRO3-dependent functions in tumour cells and macrophages, making it suitable for studying thrombosis and platelet aggregation.

Bleselumab (ASKP 1240) is a humanised monoclonal antibody targeting CD40, characterised by high affinity (Kd = 0.24 nM), blocking the interaction between CD40 and its ligand CD40L and inhibiting immune responses, and is indicated for the prevention of organ transplant rejection.

Anti-CD40 Antibody (G28.5) is a chimeric mouse IgG1, κ antibody that specifically targets human CD40. The recommended isotype control for Anti-CD40 Antibody (G28.5) is Mouse IgG1 kappa, Isotype Control.

Anti-TNFRSF5/CD40 Antibody is a highly specialized monoclonal antibody target the human tumor necrosis factor receptor superfamily member 5, which is also widely known as CD40, modulation of co-stimulatory signaling pathways and immune cell activation across various preclinical experimental models to regulate humoral immunity and dendritic cell maturation.

Anti-Mouse CD40 Antibody (FGK4.5/FGK45) is a rat-derived IgG2a monoclonal antibody targeting mouse CD40, a type I transmembrane glycoprotein within the tumor necrosis factor receptor (TNFR) superfamily. CD40 functions as a costimulatory molecule, activating B cells, dendritic cells, monocytes, and other antigen-presenting cells (APC), thereby enhancing antitumor T cell responses.

Dri-c21045 showed concentration-dependent inhibition of NF- B activation and all CD40L induced by B cell proliferation. IC50 was 17.1 M and 4.5 M, respectively.Dri-c21045 is an effective selective inhibitor of CD40-CD40L synergistic stimulator protein-pro

RCD405 is a bronchodilator that exerts a relaxing effect by directly acting on human airway smooth muscle (hASM), with an EC50 value of 12 μM for histamine-induced contraction and 45.71 μM for carbachol-induced contraction. It inhibits cholinergic and histaminergic tension and reduces contractions induced by electrical field stimulation (EFS). RCD405 shows potential for research in asthma and chronic obstructive pulmonary disease (COPD).

TNF-α-IN-2 is an effective and orally active TNFα inhibitor that distorts the TNFα trimer upon binding, causing abnormal signal transduction when it binds to TNFR1, and can be used to study rheumatoid arthritis.

BIO8898, a potent inhibitor of the CD40-CD154 interaction, effectively prevents soluble CD40L from binding to CD40-Ig, demonstrating an inhibitory concentration (IC 50) value of 25 µM. Additionally, BIO8898 suppresses CD40L-induced apoptosis [1].

Ruplizumab (BG 9588) is a humanized IgG1κ-like monoclonal antibody against CD40L. Ruplizumab is used in the study of neurological and immune system disorders.

Iscalimab (CFZ-533) is a humanized monoclonal antibody targeting CD40, used in research on myasthenia gravis and Sjögren's syndrome.

Letolizumab (BMS-986004) is a dimeric antibody targeting CD40L for the expression of mutant IgG1 that lacks effector functions including Fc binding and complement binding.1 Letolizumab does not induce platelet activation in vitro and does not affect coagulation factors or platelet counts/function after repeated dosing in non-human primates.

Ravagalimab (ABBV-323) is a CD40 antagonist monoclonal antibody with an EC50 of 3.7 nM. Ravagalimab is being investigated for the treatment of inflammatory diseases such as Crohn’s disease and Sjögren’s syndrome (SS). Research focuses on evaluating its pharmacological activity, efficacy, and safety in patients with primary Sjögren’s syndrome (pSS), highlighting its role in immune modulation.

DRI-C21041 is a potent inhibitor of the CD40/CD40L interaction, demonstrating an inhibitory concentration 50 (IC50) value of 0.31 μM. It effectively suppresses the immune response triggered by alloantigen [1].

DRI-C25441 is a potent inhibitor of the CD40-CD40L interaction, exhibiting an IC50 value of 0.36 μM, and is capable of suppressing the immune response triggered by alloantigen [1].

Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1) is an IgG1, κ inhibitor antibody derived from mouse, designed to target and inhibit mouse CD40L/CD154.

Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) is an IgG2a, κ inhibitory antibody derived from mice, specifically targeting murine CD40L/CD154.

Anti-Monkey/Human CD40L/CD154 Antibody (5C8) is an IgG2a inhibitor derived from mice that targets CD40L/CD154 in monkeys and humans.

Anti-Mouse CD40L/CD154 Antibody (MR-1) is an IgG antibody inhibitor derived from an American hamster, specifically targeting mouse CD40L/CD154.